For many patients struggling with chronic rhinitis, medical management does not provide the long-lasting relief they seek, and they remain tied to tissues and sprays to cope with their daily symptoms.
Most current, in-office rhinitis treatments are not comprehensive solutions, and surgical options like septoplasty, turbinate reduction, or other ablative technologies have mixed patient responses and may not alleviate all symptoms.
Compact and portable, the Aerin® Console and the RhinAer Stylus fit seamlessly into any clinic, office, or hospital environment. RhinAer is a convenient and efficient treatment option to integrate into your practice.
RhinAer treats the root causes of rhinorrhea / post-nasal drip and congestion in a single session.
The RhinAer stylus employs proprietary, temperature-controlled radiofrequency (RF) technology optimized for the nasal airway. Once the stylus is activated, the Aerin System automatically maintains the tip’s target temperature for therapeutic benefit while sparing surrounding tissue, including mucosa.
Patients undergoing the treatment experience minimal discomfort and recovery time.* In a recent study with the Aerin Console, there was no aerosol generation above background levels, thereby enhancing safety for physicians and staff.1
2-Year results from the RhinAer pivotal trial2
88.2% of patients were classified as responders after achieving ≥30% reduction in rTNSS compared to baseline.
65.5% overall rTNSS reduction with all rTNSS sub-scores (rhinorrhea, nasal congestion, nasal itching, and sneezing) showing statistically significant (p<.001) reduction over baseline at 24 months.
At 24-months post-nasal drip and chronic cough symptom scores remained significantly (p<.001) improved from baseline at all follow-up time points.
Treatment resulted in statistically significant mean rTNSS improvements for patients suffering from chronic rhinitis of allergic, non-allergic, and unknown etiologies, (p<0.001)
NO serious adverse events related to the device and/or procedure were observed
NO device- or procedure-related headaches were reported in the Pivotal Study through 2 years
Study design: Prospective, multi-center, single-arm study was conducted to evaluate the safety and efficacy of the RhinAer® Stylus (RhinAer) on patients with chronic rhinitis symptoms for at least 6 months duration.
Patients: Initial Pivotal Study included a total of 50 patients treated with RhinAer across five US centers with follow-up at 1-, 3-, 6- and 12-months post-procedure. Thirty-four (34) patients completed extended follow-up through 24 months.
“I feel like I can live again and do things I like to do. I’m not sneezing. I’m not blowing my nose. It’s just amazing."
* Individual results may vary
The RhinAer Stylus plugs into the compact and portable Aerin® Console. The console may also be used with the VivAer® Stylus to treat the entire nasal valve and provide lasting relief for patients suffering from nasal airway obstruction.VivAer.com